Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/46875
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRashid H.N.-
dc.contributor.authorMichail M.-
dc.contributor.authorRamnarain J.-
dc.contributor.authorNasis A.-
dc.contributor.authorNicholls S.J.-
dc.contributor.authorCameron J.D.-
dc.contributor.authorGooley R.P.-
dc.date.accessioned2022-04-04T06:11:05Z-
dc.date.available2022-04-04T06:11:05Z-
dc.date.issued2022-03-06en
dc.identifier.citationJournal of Cardiovascular Computed Tomography. 16(2) (pp 168-173), 2022. Date of Publication: 01 Mar 2022.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/46875-
dc.description.abstractBackground: Hypo-attenuated leaflet thickening (HALT) may occur following transcatheter aortic valve replacement (TAVR), however, it remains unclear if HALT is a predictor of haemodynamic valve deterioration (HVD). Aim(s): To determine the impact of HALT on the occurrence of HVD. Method(s): We prospectively evaluated 186 patients for the presence of HALT at a median of 6 weeks following TAVR (Interquartile-range [IQR] 4-12 weeks). HALT depth and area were measured. HVD encompassed any of the following: mean gradient >=20 mmHg with an increase in gradient >=10 mmHg from baseline, Doppler velocity index reduction >=0.1 or new moderate-to-severe valvular regurgitation. Routine echocardiograms at discharge, one month and annually, were assessed by echo-cardiologists that were blinded to the HALT status. Result(s): LT prevalence was 17.7% (33/186). HVD was present in 8.6% (16/186) at a median follow-up of 2 years (IQR 1-3); two required valve re-intervention and five required anticoagulation. HALT was the only independent predictor of HVD on multivariate analysis (OR 33.3, 95%CI 7.4-125). Patients with HALT were more likely to develop HVD, require repeat valve intervention and have higher trans-valvular gradients at up to 3-year follow-up. Patients with HALT had a median cumulative thickness of 2.9 mm (IQR 1.9-4.7) and area of 64.2 mm2 (IQR 40.9-91.6). Thresholds for HALT in predicting HVD were a cumulative depth of 2.4 mm (Specificity 94.1%, Sensitivity 75.0%, AUC = 0.87) and cumulative area of 28 mm2 (Specificity 92.2%, Sensitivity 81.3%, AUC = 0.86). Conclusion(s): HALT is an independent predictor of HVD, which exhibits specific depth and area thresholds to predict HVD. CT following TAVR may determine patients at risk of HVD.Copyright © 2021-
dc.publisherElsevier Inc.-
dc.relation.ispartofJournal of Cardiovascular Computed Tomography-
dc.subject.meshaged-
dc.subject.meshanticoagulant therapy-
dc.subject.meshbody mass-
dc.subject.meshcerebrovascular accident-
dc.subject.meshchronic obstructive lung disease-
dc.subject.meshcomputer assisted tomography-
dc.subject.meshcoronary artery bypass graft-
dc.subject.meshechocardiography-
dc.subject.meshfour dimensional computed tomography-
dc.subject.meshheart cycle-
dc.subject.meshheart failure-
dc.subject.meshpercutaneous coronary intervention-
dc.subject.meshpractice guideline-
dc.subject.meshsurface property-
dc.subject.meshtranscatheter aortic valve implantation-
dc.subject.meshtransient ischemic attack-
dc.subject.meshvalve deterioration/co acetylsalicylic acid/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshclopidogrel/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshheparin/ia [Intraarterial Drug Administration]-
dc.subject.meshheparin/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshiohexol/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshprotamine/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshaortic valve prosthesis-
dc.subject.meshcomputed tomography scanner-
dc.subject.meshheart valve bioprosthesis-
dc.subject.meshpercutaneous aortic valve-
dc.subject.meshpercutaneous aortic valve bioprosthesis-
dc.subject.meshhaemodynamic valve deterioration/co hypoattenuated leaflet thickening/co CoreValve/Evolut-
dc.titleThe impact of hypo-attenuated leaflet thickening on haemodynamic valve deterioration following transcatheter aortic valve replacement.-
dc.typeArticle-
dc.identifier.affiliationCardiology (MonashHeart)-
dc.identifier.affiliationRespiratory and Sleep Medicine-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.jcct.2021.11.013-
dc.publisher.placeUnited States-
dc.identifier.pubmedid34852974 [https://www.ncbi.nlm.nih.gov/pubmed/?term=34852974]-
dc.identifier.institution(Rashid, Ramnarain, Nasis, Nicholls, Cameron, Gooley) Monash Heart, Monash Health and Monash Cardiovascular Research Centre, Monash University, Australia-
dc.identifier.institution(Michail) Sussex Cardiac Centre, University Hospital Sussex NHS Trust, Brighton, United Kingdom-
dc.description.grantOrganization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia-
dc.description.grantOrganization: (RACP) *Royal Australasian College of Physicians* Organization No: 501100001232 Country: Australia-
dc.description.grantOrganization: *National Heart Foundation of Australia* Organization No: 501100001030 Country: Australia-
dc.description.grantOrganization: *National Heart Foundation of Australia* Organization No: 501100001030 Country: Australia-
dc.identifier.affiliationmh(Rashid, Ramnarain, Nasis, Nicholls, Cameron, Gooley) Monash Heart, Monash Health and Monash Cardiovascular Research Centre, Monash University, Australia-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeArticle-
item.cerifentitytypePublications-
crisitem.author.deptCardiology (MonashHeart & Victorian Heart Institute)-
Appears in Collections:Articles
Show simple item record

Page view(s)

16
checked on Nov 24, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.